Preemadonna and InsitU Skincare are among the first five startups selected for L’Oreal and Founders Factory’s accelerator program, announced in May 2016. The French beauty juggernaut and London-based mentorship firm teamed up to nurture fledgling businesses in the beauty tech field, with the former aspiring to “deeply connect itself to a global ecosystem of world-class startups and entrepreneurs.”
Among 180 applications from around the globe, Preemadonna Inc.’s Nailbot printer, which applies designs from a mobile app directly to users’ nails, and InsitU, a direct-to-consumer provider of personalized skin care, have won spots in L’Oreal SA and Founders Factory’s accelerator program for beauty tech startups.
According to the Jan. 23 announcement, the partners have selected five startups in total to participate in the six-month program,...
Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
